A new ecologically inspired paradigm in cancer treatment known as "adaptive therapy" capitalizes on competitive interactions between drug-sensitive and drug-resistant subclones. The goal of adaptive therapy is to maintain a controllable stable tumor burden by allowing a significant population of treatment sensitive cells to survive. These in turn suppress proliferation of the less fit resistant populations. This adaptive approach means that each patient's treatment is truly personalized based on the tumor's response and current state rather than a one-size-fits-all fixed treatment regime. However, there remain several open challenges in designing adaptive therapies, particularly in extending these therapeutic concepts to multiple treatments.
concepts (evolutionary cycles, evolutionary search space, and evolutionary velocity) can aid in the selection of drugs and design of treatment schedules in multi-drug adaptive therapy. Schematic of cancer clonal evolution under therapy. A) Conventional sequential therapy of two treatments selects for a clone resistant to treatment one (red) upon tumor relapse and subsequently a clone resistant to treatment two (green). B) Adaptive therapy maintains a stable tumor volume by introducing treatment holidays. Drug sensitive clones (blue) suppress the growth of less fit resistant clones (red). However, resistance still eventually occurs. C) One proposed adaptive multi-drug strategy is to alternately switch between drugs during each on-off cycle of tumor burden. D) An alternative multi-drug adaptive strategy is to administer both drugs simultaneously during each on-off cycle, leading to a doubly-resistant resistant clone (yellow).
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Biopsy cycle is completed when tumor composition matches starting point The goal of adaptive therapy is to maintain a stable tumor volume while controlling the composition of the tumor with respect to cell type frequencies (stored in the state vector, x). A frequency-dependent "cycle" is a paradigm of tumor control which employs a succession of treatments that returns the state of the tumor composition back to the initial state. A cycle of five weeks is shown here: x 5 ≈ x 1 . In this example, it is assumed that a single unvarying course of action would result in an unacceptable tumor composition of resistant cell types.
The goal of adaptive therapy is to maintain a controllable stable tumor burden by 46 allowing a significant population of treatment sensitive cells to survive (see Fig. 1B , 47 blue). These readily treatable sensitive cell serve to supress the proliferation of the less 48 fit resistant populations (see Fig. 1B , red). Adaptive therapies have now been tested 49 experimentally [23, 23, 24] and are currently being applied across multiple clinical trials 50 (NCT02415621; NCT03511196; NCT03543969; NCT03630120) at the Moffitt Cancer
51
Center [25] . These adaptive therapies capitalize on competition for space and resources 52 between drug-sensitive and slow growing drug-resistant populations [26] [27] [28] . 53 Steering patient-specific evolution 54 This adaptive approach means that each patient's treatment is truly personalized based 55 on the tumor's state and response rather than a one-size-fits-all fixed treatment 56 regime [29] .
There remain several open challenges in designing adaptive therapies. First, 57 treatments can aim to steer and control the eco-evolutionary dynamics to where the tumor finds itself in an evolutionary dead end [30] , an evolutionary double-bind [31] [32] [33] , 59 or evolutionarily stable control [18, 27, 34 ]. Yet, for clinical practice, how to design such 60 therapies remains difficult. Second, it's not yet clear how to extend these evolutionarily 61 enlightened therapeutic concepts to multiple treatments. Two schematic examples are 62 illustrated in Fig. 1C and 1D. Is it evolutionarily optimal to reproduce the single drug 63 adaptive therapy in a sequential (Fig. 1C ) setting or in combination ( Fig. 1D) ? 64 Synergizing treatments such that evolving resistance to one drug makes cells more 65 susceptible to another requires mathematical modeling as well as improved monitoring 66 methods [35, 36] .
67 Figure 2 provides a schematic of steering the tumor into "cycles" of tumor evolution. 68 A cycle is defined as a treatment regimen that steers the tumor into periodic and 
77
A trial may use sequences of n available drugs either alone or in combination (shown 78 for n = 2 in figure 2). We employ the terminology "treatment" to indicate the 2 n 79 possible combinations: no drug, single drug, or combination therapy. These treatments 80 can be administered in any arbitrary sequence with the goal of controlling m cell types. 81 An adaptive trial for metastatic castrate resistant prostate cancer (NCT02415621) uses 82 only two treatments: 1. Lupron and 2. Lupron & Abiraterone. Likewise, an adaptive 83 trial for advanced BRAF mutant melanoma (NCT03543969) administers Vemurafenib 84 and Cobimetinib in combination, followed by no treatment. Both trials use only two 85 treatments out of the four (2 2 ) combinations possible with two drugs (no treatment; first 86 drug only; second drug only; first and second drug in combination therapy). Opening up 87 trial design to include the full range of complexity (i.e. 2 n ) may allow for greater tumor 88 control, but the treatment administered at each clinical decision time point must be 89 chosen with care and forethought, to steer the tumor into a desirable evolutionary state. 90 Adaptive therapy has been attempted clinically using proxy measurements for tumor 91 volume such as prostate-specific antigen marker (PSA) for prostate or lactate 92 dehydrogenase (LDH) for melanoma. While these blood biomarkers are crude 93 measurements of tumor burden, there have been many recent advances in reliable 94 methods of monitoring tumor evolution using circulating tumor DNA as an informative, 95 inherently specific, and highly sensitive biomarker of metastatic cancers (see [37] ). As 96 monitoring methods mature, so must methods of prediction and quantification of 97 evolution [25, 38, 39] . To that end, the purpose of this paper is to introduce the following 98 three concepts to consider in the pursuit of designing multi-drug adaptive therapies: As seen in Fig. 1B ,C, and D, the goal of an adaptive therapy is to maintain a stable 103 tumor volume consisting of a substantive drug-sensitive population (blue) that is able to 104 out-compete and suppress resistant populations (red, green, yellow). Adaptive therapy 105 maintains a stable tumor volume in favor of controlling the tumor composition (i.e. x as shown in figure 2 ) and introduces a case study to illustrate these concepts.
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Materials and methods
113
Evolutionary game theory (EGT) is a mathematical framework that models the population at large [40] [41] [42] . As a game, the payoff to an individual depends both on 118 its strategy and the strategies of others in the population. As an evolutionary game, the 119 payoffs to individuals possessing a particular strategy influences the changes in that strategy's frequency. A strategy that receives a higher than population-wide average 121 payoff will increase in frequency at the expense of strategies with lower than average 122 payoffs. Such frequency-dependent mathematical models have shown success in 123 modeling competitive release in cancer treatment [13] , designing optimal cancer 124 treatment [43] [44] [45] , evolutionary double binds [32] , glioblastoma progression [46] , 125 tumor-stroma interactions [47] , the emergence of invasiveness in cancer [48] as well as in 126 co-culures of alectinib-sensitive and alectinib-resistant non-small cell lung cancer [49] .
127
Frequency-dependent models of tumor evolution are particularly suited for studying 128 tumor control (i.e. "cycles" of tumor evolution), determining the set of possible 129 evolutionary dynamics (i.e. evolutionary search space), and timing of evolution (i.e. 130 evolutionary velocity). The next section introduces a simplified extension of a 131 previously published model of prostate cancer [25, 50] . This case study introduces and 132 develops these generalizable concepts for designing multi-drug adaptive therapy 133 treatment schedules for three cell types (m = 3 phenotypes; figure 2) under two drug 134 treatments (n = 2 drugs; figure 2 ). In principle, the concepts applied to this particular 135 case study in the next section can be extended to an arbitrary number of available 136 treatment combinations for desired control of an arbitrary number of cell types.
137
Case study: metastatic castrate resistant prostate cancer 138 In progressive prostate cancer, continuous or intermittent androgen deprivation (IAD) 139 are common treatments that generally leads to a substantial decline in tumor burden.
140
Eventually, tumor burdern rebounds as a result of the rise of castrate-resistant cells [51] . 141 Upon castrate-resistance, adaptive therapy using abiraterone has shown considerable 142 treatment success. Previously, this disease was described by a population dynamics 143 model with three cell types: those that require testosterone for growth, T + , cells that In principle, there exist many frequency-dependent models of cell-cell competition 150 which could adequately characterize this system: replicator dynamics models, stochastic 151 Moran process models, spatially-explicit game theoretic representations, even 152 normalized population dynamics models. Here, we simply require a model which 153 analyzes trajectories of relative population sizes rather than absolute population sizes of 154 m cell types under treatment from combinations of n drugs. For details on the specific 155 implementation and parameterization of the model used in figures 3, 5, and 6, we refer 156 the reader to Supplemental Information and to refs. [25, 50] .
157
In order to track the state vector of the tumor, x, we set the variables x 1 , x 2 , x 3 to 158 the corresponding frequency of dependent (T + ), producers (T P ) and independent (T − ) 159 cells, respectively, such that i x i = 1. The temporal dynamics of these different 
Results
171
The goal of adaptive therapy in prostate cancer is to delay the onset of the resistant T − 172 population by well-timed switching between each treatment. This is equivalent to 173 switching between each triangular phase portrait in figure 3 before reaching the 174 resistant equilibrium state of any given treatment. In theory, a periodic (closed) cycle 175 can be constructed by switching between treatments at carefully chosen times in order 176 to design schedules that are superior to continuous maximum tolerated dose [52, 53] .
177
Searching for cycles 178 For example, figure 4A shows a patient with an initial condition of roughly equal 179 fractions of each cell type (blue circle). Lupron might be administered for some time 180 (blue line) before switching to no treatment (purple line), followed by a switch to both 181 Lupron & Abiraterone (red line). This sequence of treatments arrives back at the same 182 initial condition: an evolutionary cycle. This treatment sequence can be repeated, 183 controlling the tumor. The dashed lines on figure 4A show dynamics under continuous 184 treatment which lead to respective equilibrium states, spiralling out of the evolutionary 185 cycle.
186
The identical evolutionary cycle paradigm is shown with cell fraction, x over time in 187 figure 4B . By appropriate treatment switching, the three cell types remain in 188 competition with each other, and no cell type is able to dominate but instead are 189 balanced indefinitely in closed periodic cycles thereby avoiding the emergence of 190 resistance. The tumor undergoes 3 such evolutionary cycles, where the tumor "resets" 191 back the initial state before treatment (pie charts, figure 4 ).
From this perspective, adaptive therapy benefits from treatment holidays precisely 193 because these holidays help the tumor composition be pushed into an approximate cycle. 194 Yet, when slightly off, resistance still eventually occurs in adaptive therapy regimes 195 when not on an exact cycle (Fig. 1B, red) . By observation, many such cycles exist in 196 the state space shown in Fig. 3D : for example, traveling down any Lupron trajectory 197 (blue), switching to a no treatment trajectory (purple) and so on, repeated ad infinitum. 198 Where do such cycles exist? Which cycles are preferable? To answer these questions, the 199 next section introduces concepts of evolutionary search space and evolutionary velocity. 200
Evolutionary search space 201
These same phase portraits can be drawn for each pairwise treatment combination (Fig. 202  5) . Each treatment has an associated equilibrium (solid circles), which can be connected 203 by a single evolutionary trajectory. These two connecting trajectories represent a desired. A tumor with a high composition of resistant cells may need to navigate to a 242 fast dynamics region to rapidly decrease the resistant subpopulation. Alternatively, an 243 adaptive regime may capitalize on slow velocities regions that ensure slow evolutionary 244 dynamics on treatment holidays.
245
Frequency dynamics models allow for monitoring and control of the velocity of a 246 single cell type (see Fig. 6 D -L). For example, under continuous Lupron & Abiraterone 247 treatment, the velocity of the T − population is positive for most of the state space (see 248 Fig. 6L ). In order to control the T − population, it's necessary to switch to a new 249 treatment: Fig. 6J or Fig. 6K . Depending on the current tumor composition, no 250 treatment or Lupron may be desirable for negative T − velocity (blue).
251
Discussion 252
In the design of multi-drug adaptive therapy, the optimal method of combining 253 therapies in an additive or sequential manner is unclear. A key observation is that the 254 goal of adaptive therapy is to maintain a stable tumor volume in favor of designing 255 therapies that alter tumor composition. We advocate for the use of frequency-dependent 256 competition models (and in particular evolutionary game theory) to design novel 257 multi-drug adaptive therapy regimens. This is a promising modeling approach, and 258 more work must be done combining population models of changing tumor volume with 259 frequency dependent models of changing tumor fraction in order to eliminate clinically 260 unfeasible treatment schedules from consideration.
261
While it's clear that tumors evolve in response to treatment, it's proved difficult to 262 exploit evolutionary principles to steer tumor evolution in an ideal direction. One 263 limitation of current adaptive therapy clinical trials is the limited selection of drugs and 264 limited monitoring methods. Even despite the lack of monitoring the exact state of the 265 tumor composition, the technique of maintaining a substantial drug-sensitive population 266 for extended tumor control has shown promise in mathematical models as well as inter-cell type interactions: 1) T + cells with no exogenous testosterone are the least competitive cell type and 2) the competitive effect of T − cells is stronger on TP cells than on T+ cells. 
